Answers are grounded in this paper and cite their sources.
Escherichia coli (E. coli) harboring extended-spectrum beta-lactamase (ESBL) enzymes poses a significant antimicrobial resistance threat, compromising β-lactam efficacy. Here, we report the draft genome and genomic characterization of ESBL-producing E. coli strain S11, isolated from municipal tap water in South Dhaka, Bangladesh, sequenced using the Illumina NextSeq 2000 platform. The draft assembly comprised 4,990,311 bp distributed across 139 contigs of at least 200 bp, with an N50 value of 182,030 bp, an N90 value of 54,615 bp, a largest contig of 543,452 bp, and a GC content of 50.52% and an estimated nominal sequencing coverage of ~ 202.9×. ABRicate/CARD analysis identified 48 antimicrobial resistance-associated determinants, including intrinsic efflux and regulatory loci. Resistome screening identified the ESBL-associated gene blaCTX-M-15 together with other beta-lactamase and aminoglycoside resistance genes, including blaTEM-1B, blaOXA-1, blaCMY-145, aac(3)-IIa, and aac(6’)-Ib-cr. PlasmidFinder detected Col156, Col8282, and IncI1 replicons. PathogenFinder2 predicted human pathogenic potential with a mean score of 0.9807. Collectively, these genomic findings indicate that this isolate carries antimicrobial resistance determinants and plasmid replicons, providing genomic data that may be useful for future comparative studies of environmental E. coli . Raw reads of strain S11 are available in NCBI under SRA SRR39239575, BioProject PRJNA1478760 and BioSample SAMN61018556 and assembly is available as GenBank WGS project JCAKBG000000000.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: